Online citations, reference lists, and bibliographies.
← Back to Search

Relationship Between Expression Of EGFR In Gastric Cancer Tissue And Clinicopathological Features.

M. Gao, X. Liang, Zi-sen Zhang, Wang Ma, Z. Chang, Ming-Zhi Zhang
Published 2013 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
OBJECTIVE To investigate the relationship between the expression of epidermal growth factor receptor (EGFR) in gastric cancer and the clinicopathological features and prognosis. METHODS A total of 78 paraffin specimens of gastric cancer operation were collected. The immunohistochemical method was used to detect the expression of EGFR in 78 cases of gastric cancer and 20 cases of adjacent normal tissue. The relationship between the high expression of EGFR and clinicopathological features was analyzed. RESULTS EGFR positive expression rate in the 78 cases of gastric cancer tissue was 57.7 % (45/78), while EGFR was not expressed in 20 cases of adjacent normal tissue. The high EGFR expression was positively correlated with the position of gastric cancer, tumor size, cell differentiation, invasive depth, lymph node metastasis and TNM staging, yet having no obvious relation with gender or age. CONCLUSIONS EGFR expression level in gastric cancer is closely related to the incidence and development of gastric cancer, which can provide a theoretical basis for the targeted therapy for gastric cancer with EGFR as the target.
This paper references
10.1186/1471-2407-8-10
Epidermal growth factor receptor structural alterations in gastric cancer
C. Moutinho (2007)
10.1136/gutjnl-2011-301839
A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets
N. Deng (2012)
10.1200/JCO.2004.22.14_SUPPL.3510
Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin.
H. Lenz (2004)
The EerbB signaling network receptor heterodimeri-zation in development and cancer
MA Olayioye (2001)
10.1093/emboj/19.13.3159
The ErbB signaling network: receptor heterodimerization in development and cancer
M. Olayioye (2000)
Tyrosin phosphorylation if betacaten in and plakoglokin enhanced by hepatocyet growth factor and epidermal growth factor in human carcinoma cells
S Shibamoto (1994)
10.1200/JCO.2011.29.27_SUPPL.259
The use of complementary and alternative medicine (CAM) by Irish patients with breast cancer.
D. M. Graham (2011)
10.1038/modpathol.3800777
Non-incidental coamplification of Myc and ERBB2, and Myc and EGFR, in gastric adenocarcinomas
Fumihiko Mitsui (2007)
10.1186/1476-4598-9-121
Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition
S. Corso (2009)
10.3109/15419069409097261
Tyrosine Phosphorylation of β-Catenin and Plakoglobin Enhanced by Hepatocyte Growth Factor and Epidermal Growth Factor in Human Carcinoma Cells
S. Shibamoto (1994)
ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
J. Anido (2003)
10.3892/OR.15.5.1205
Mutations of the epidermal growth factor receptor gene in gastrointestinal tract tumor cell lines.
Toshimoto Kimura (2006)
10.1200/JCO.2006.24.18_SUPPL.3510
Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE-Study.
H. Hochster (2006)
10.1038/sj.bjc.6604848
Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant
F. Molinari (2009)
10.1200/JCO.2010.28.15_SUPPL.4006
CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer.
P. Enzinger (2010)
260 - 264 264 phase 栻 study of three standard chemotherapy regiments ( ECF , IC , FOLFOX ) plus cetuximab in metastatic esophageal and GE junction cancer
AF Okines
10.2174/1389450053765879
The ErbB receptors and their ligands in cancer: an overview.
N. Normanno (2005)
Estimates of worldwide burden of cancer in2008: GLOBOCAN
J Ferlay (2008)
10.1200/JCO.2010.29.2847
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial.
A. Okines (2010)
10.1111/j.1742-4658.2009.07448.x
Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer
T. Mitsudomi (2010)
10.1158/1078-0432.CCR-07-1509
Dose and Schedule Study of Panitumumab Monotherapy in Patients with Advanced Solid Malignancies
L. Weiner (2008)
10.1200/JCO.2011.29.15_SUPPL.4013
Impact of human epidermal growth factor receptor (EGFR) and ERBB2 (HER2) expressions on survival in patients with stage II/III gastric cancer, enrolled in the ACTS-GC study.
M. Terashima (2011)
10.1074/jbc.M207555200
Mechanism of Epidermal Growth Factor Regulation of Vav2, a Guanine Nucleotide Exchange Factor for Rac*
P. Tamás (2003)
10.1245/s10434-007-9596-0
Expression of Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) is an Independent Prognostic Indicator of Worse Outcome in Gastric Cancer Patients
E. Lieto (2007)
10.1093/JJCO/HYI089
Usefulness and limitation of multiple endoscopic biopsy sampling for epidermal growth factor receptor and c-erbB-2 testing in patients with gastric adenocarcinoma.
M. Kimura (2005)
10.1002/ijc.25516
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
J. Ferlay (2010)
10.1186/1471-2407-12-524
The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer
A. Atmaca (2012)



This paper is referenced by
10.21037/tcr.2018.03.15
Upregulation of programmed death ligand 1 and epidermal growth factor receptor is associated with poor prognosis in gastric cancer
Wei Wei (2018)
10.1371/journal.pcbi.1005428
Oncodomains: A protein domain-centric framework for analyzing rare variants in tumor samples
T. Peterson (2017)
10.1016/j.gene.2015.11.010
Interpreting the distinct and shared genetic characteristics between Epstein-Barr virus associated and non-associated gastric carcinoma.
Xixun Wang (2016)
10.21037/TCR.2016.11.29
Is there a role for epidermal growth factor receptor inhibition in the treatment of advanced esophagogastric tumours
S. Thavaneswaran (2016)
10.1038/s41598-018-30352-6
CT textural analysis of gastric cancer: correlations with immunohistochemical biomarkers
Shunli Liu (2018)
10.1371/journal.pone.0111146
Molecular Integrative Clustering of Asian Gastric Cell Lines Revealed Two Distinct Chemosensitivity Clusters
M. L. Choong (2014)
10.17709/2409-2231-2019-6-4-6
Activation of different growth factor systems in tissues of adenocarcinoma and signet-ring cell carcinoma of the stomach
O. Kit (2019)
10.3389/fmicb.2020.00090
Gastric Damage and Cancer-Associated Biomarkers in Helicobacter pylori-Infected Children
Sergio George (2020)
10.3390/nu11092113
Lycopene Inhibits Activation of Epidermal Growth Factor Receptor and Expression of Cyclooxygenase-2 in Gastric Cancer Cells
Hwana Han (2019)
10.1515/biol-2016-0043
The association between EGFR expression and clinical pathology characteristics in gastric cancer
Y. Chen (2016)
The O-glycosylating enzyme GALNT2 suppresses the malignancy of gastric adenocarcinoma by reducing EGFR activities.
Wan-ting Hu (2018)
Semantic Scholar Logo Some data provided by SemanticScholar